Skip to nav Skip to content
  • Cancer Type: Malignant Hematology
  • Study Type: Treatment
  • NCT#: NCT06297226
  • Phase: Phase II
Learn More
  • Overview

    Study Title:

    A Phase 2, Open-Label, Multicenter Study of BMS-986393, a GPRC5D-directed CAR T Cell Therapy in Adult Participants with Relapsed or Refractory Multiple Myeloma (QUINTESSENTIAL)


    Primary: To evaluate the efficacy of BMS-986393 in participants with quadruple class exposed R/R MM having received at least 4 prior LOT. Secondary: -To further evaluate the efficacy of BMS-986393 in participants with quadruple class exposed R/R MM having received at least 4 prior LOT and 3 prior LOT. -To assess the safety of BMS-986393 among participants with R/R MM. -To assess additional efficacy parameters. -To assess the cellular kinetics of BMS-986393. -To assess key MM symptoms, functioning, and overall HRQoL. -To measure HCRU. Exploratory: -To evaluate the capacity of physiologic measurements captured by wearable biosensors to predict the onset of clinical events, including but not limited to CRS after BMS-986393. -To assess IMG of BMS-986393. -To assess the presence of RCL. -To assess MM antigen expression. -To assess soluble MM pharmacodynamic biomarker and soluble factors of immune response kinetics. -To molecularly profile CAR T cells, tumor, and microenvironment. -To assess patient-reported tolerability based on the PRO-CTCAE. -To assess the impact on health utility scores based on EQ-5D-5L, EORTC QLC-C30, and EORTC QLQ-MY20. -To validate the computerized algorithm to programmatically derive response based on IMWG criteria. -To assess relationship between PK parameters and selected clinical endpoints (eg, measures of toxicities, effectiveness, IMG, and/or biomarkers).

  • Treatments


    Cell Therapy; Chemotherapy (NOS)


    BMS-986393 (); Tocilizumab (); cyclophosphamide (); cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)

  • Inclusion Criteria

      Key Inclusion Criteria:
    • Participants at least 18 years of age or majority, inclusive, with documented diagnosis of MM as per International Myeloma Working Group (IMWG) criteria.
    • Participant must have received at least 4 classes of MM treatment (including an IMiD, PI, anti-CD38 mAb, and anti-BCMA therapy), and at least 3 prior LOT. Participants must have documented disease progression during or after their last anti-myeloma regimen (as per IMWG).
    • Participants must have measurable disease during screening.
    • Participant must have Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
    • Adherence to contraception requirements.
  • Exclusion Criteria

      Key Exclusion Criteria:
    • Participant with known active or history of central nervous system involvement with MM.
    • Participant has active systemic fungal, bacterial, viral, or other infection despite appropriate anti-infective treatment at the time of leukapheresis.
    • Participant has received any prior therapy directed at GPRC5D or has received other prior treatment for MM without the required washout prior to leukapheresis.
    • Participant has inadequate organ function (per protocol definition).

If you are interested in learning more about clinical trials, our clinical trial navigators can discuss your options and recommend opportunities that may be suitable for you. Call 813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form.

Clinical Trial Search